- Home
- Publications
- Publication Search
- Publication Details
Title
A tumor-targeted immune checkpoint blocker
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 116, Issue 32, Pages 15889-15894
Publisher
Proceedings of the National Academy of Sciences
Online
2019-07-23
DOI
10.1073/pnas.1905646116
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease
- (2018) Noha Abdel-Wahab et al. ANNALS OF INTERNAL MEDICINE
- Antibodies to watch in 2018
- (2018) Hélène Kaplon et al. mAbs
- Antibodies to watch in 2019
- (2018) Hélène Kaplon et al. mAbs
- 68Ga-DOTA-GGNle-CycMSHhex targets the melanocortin-1 receptor for melanoma imaging
- (2018) Jianquan Yang et al. Science Translational Medicine
- Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy
- (2017) Robert Torphy et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Imaging of Programmed Cell Death Ligand 1: Impact of Protein Concentration on Distribution of Anti-PD-L1 SPECT Agents in an Immunocompetent Murine Model of Melanoma
- (2017) Jessie R. Nedrow et al. JOURNAL OF NUCLEAR MEDICINE
- Key amino acid residue in Melanocortin-1 receptor (melanocyte α-MSH receptor) for ligand selectivity
- (2017) Yingkui Yang et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody
- (2017) Jonathan K. Fallon et al. Oncotarget
- Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer
- (2016) Brant A. Inman et al. CLINICAL CANCER RESEARCH
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor
- (2016) Rong Deng et al. mAbs
- Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor
- (2016) A. J. Vandeveer et al. Cancer Immunology Research
- Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer
- (2015) Anders Josefsson et al. CANCER RESEARCH
- Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy
- (2015) Keishi Adachi et al. CANCER SCIENCE
- P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma
- (2015) A. Ribas et al. EUROPEAN JOURNAL OF CANCER
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
- (2015) A. Sivan et al. SCIENCE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- Malignant melanoma and melanocortin 1 receptor
- (2013) A. A. Rosenkranz et al. BIOCHEMISTRY-MOSCOW
- Current management and novel agents for malignant melanoma
- (2012) Byung Lee et al. Journal of Hematology & Oncology
- Cellular and Molecular Requirements for Rejection of B16 Melanoma in the Setting of Regulatory T Cell Depletion and Homeostatic Proliferation
- (2012) J. Kline et al. JOURNAL OF IMMUNOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Final Version of 2009 AJCC Melanoma Staging and Classification
- (2009) Charles M. Balch et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation